Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Organogenesis Holdings's accounts receivables for the quarter that ended in Jun. 2026 was $100.9 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 215.17.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Organogenesis Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-0.95.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Organogenesis Holdings's accounts receivable are only considered to be worth 75% of book value:
Organogenesis Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Organogenesis Holdings Accounts Receivable Related Terms
Organogenesis Holdings Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $100.9 Mil mean?
Organogenesis Holdings (ORGO) has a Accounts Receivable of $100.9 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Accounts Receivable too high?
Organogenesis Holdings' current Accounts Receivable is $100.9 Mil. Overall, Organogenesis Holdings has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Accounts Receivable compare to AKBA and TKNO?
Organogenesis Holdings' Accounts Receivable of $100.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Accounts Receivable is $100.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.05, compared to a current price of $1.79 — trading 41.3% below its estimated fair value. The current Accounts Receivable is $100.9 Mil. Organogenesis Holdings' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Accounts Receivable is $100.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (ORGO) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of $1.79 is trading 41.3% below its estimated GF Value™ of $3.05.
GuruFocus considers Organogenesis Holdings to be Possible Value Trap.
Key valuation signals for ORGO:
Accounts Receivable: $100.9 Mil
GF Value™: $3.05 vs. price of $1.79 (41.3% below fair value)
No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
62GF Score
Get the complete analysis for ORGO
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGO has been successfully added to your 
